AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (Previously Presented) A stable, aqueous formulation comprising natalizumab, a phosphate buffer, a polysorbate, and sodium chloride.

2. (Original) The formulation of claim 1, wherein the polysorbate is polysorbate 80.

3. (Original) The formulation of claim 2, wherein the polysorbate 80 is present in an amount of about 0.001% to about 2.0% (w/v).

4. (Original) The formulation of claim 3, wherein the polysorbate 80 is present in the amount of about 0.02% (w/v).

5. (Previously Presented) The formulation of claim 1, wherein natalizumab is present in the amount of about 0.1 mg/mL to about 200 mg/mL.

6. (Previously Presented) The formulation of claim 5, wherein natalizumab is present in the amount of about 1.7 mg/mL to about 50 mg/mL.

7. (Previously Presented) The formulation of claim 5, wherein natalizumab is present in the amount of about 5 mg/mL.

8. (Previously Presented) The formulation of claim 5, wherein natalizumab is present in the amount of about 20 mg/mL.

9. (Original) The formulation of claim 1, wherein the formulation has a pH of about 3.0 to about 7.0.

10. (Original) The formulation of claim 9, wherein the pH is about 5.5 to about 6.5.

11. (Previously Presented) The formulation of claim 10, wherein the pH is about 6.0 +/- 0.5.

12. (Previously Presented) The formulation of claim 1, wherein the formulation is in a fixed volume and natalizumab is present in the amount of about 50 mg/mL.

13.-14. (Canceled)

15. (Previously Presented) The formulation of claim 1, wherein the phosphate buffer is at pH 6.0 +/- 0.5, the polysorbate is polysorbate 80 and is present in an amount of about 0.02% (w/v), and wherein the formulation is stable at a temperature of about 2 °C to about 8 °C for at least 6 months.

16. (Original) The formulation of claim 15, wherein natalizumab is present in an amount of about 20 mg/mL to about 150 mg/mL.

17. (Original) The formulation of claim 1, wherein the formulation is isotonic.

18. - 22. (Canceled)

23. (Previously Presented) The formulation of claim 1, wherein natalizumab is present in the amount of about 15 mg/mL to about 50 mg/mL.

24. - 26. (Canceled)

27. (Withdrawn) A method of treating a patient with variable weight for a condition with a therapeutic amount of an immunoglobulin comprising administering a formulation of claim 1 to said patient wherein the condition is treated by administration of the formulation.

28. (Withdrawn) The method of claim 27, wherein the immunoglobulin is natalizumab.

29. (Previously Presented) A composition comprising a sodium phosphate, a polysorbate, natalizumab, and sodium chloride with a pH of 6.0 +/- 0.5, wherein the composition is stable when stored at about 2 °C to about 8° C for greater than 6 months.

30. (Original) The composition of claim 29, wherein the polysorbate is polysorbate 80 and is present in an amount of about 0.001% to about 2.0% (w/v).

31. (Previously Presented) The composition of claim 29, wherein natalizumab is present in an amount of about 0.01 mg/mL to about 200 mg/mL.

32. (Previously Presented) The composition of claim 29, wherein the polysorbate is polysorbate 80 and is present in the amount of about 0.02% (w/v), the sodium chloride is present in the amount of 150 mM, the phosphate buffer is present in the amount of 10 mM, and natalizumab is present in the amount of 1.7 mg/mL, 5 mg/mL , 20 mg/mL or 50 mg/mL.

33. (Withdrawn) A method of preparing a stable protein containing formulation comprising admixing sodium phosphate, sodium chloride, a polysorbate and a protein and adjusting the pH of the mixture with phosphoric acid to about pH 6.0 +/- 0.5.

34. (Withdrawn) The method of preparing a stable protein containing formulation of claim 33, wherein the sodium phosphate is present in an amount of

about 10 mM, the sodium chloride is present in an amount of about 150 mM, the polysorbate is polysorbate 80 and is present in an amount of about 0.02% (w/v) and the protein is natalizumab.

35. (Withdrawn) The method of preparing a stable protein containing formulation of claim 33, wherein natalizumab is present in an amount of about 20 mg/mL to about 200 mg/mL.

36. (Withdrawn) The method of preparing a stable protein containing formulation of claim 35, wherein natalizumab is present in an amount of about 150 mg/mL.

37. (Withdrawn) The method of preparing a stable protein containing formulation of claim 33, wherein the protein is lyophilized in the formulation of claim 1.

38. (Withdrawn) The method of preparing a stable protein containing formulation of claim 37, wherein the polysorbate is polysorbate 80 and is present in an amount of about 0.02% (w/v) and the protein is natalizumab.

39. (Withdrawn) The method of preparing a stable protein containing formulation of claim 37, wherein the formulation further comprises histidine.

40. (Withdrawn) The method of preparing a stable protein containing formulation of claim 33, wherein the protein is lyophilized in a solution comprising 5 mM histidine, 20 mg/mL sucrose and 0.02% polysorbate 80 at a pH 6, and wherein the protein is natalizumab at a concentration of 20 mg/mL.

41. (Original) An article of manufacture comprising a container holding the stable formulation of claim 1.

42. (Withdrawn) A method for treating a patient with variable weight for a condition, comprising simultaneously or sequentially administering to the patient a therapeutically effective combination of a formulation of claim 1 and a compound or therapy effective against the condition.

43. (Previously Presented) A stable, aqueous formulation comprising:
20 mg of natalizumab;
140 mM sodium chloride;
0.02% polysorbate 80 (w/v); and
10 mM sodium phosphate.

44. (Previously Presented) The formulation of claim 43, wherein the formulation is stable at about 2 °C to about 8 °C for six months.

45. (New) The formulation of claim 1, wherein the natalizumab is present in the amount of about 0.1 mg/mL to about 150 mg/mL.